



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/425487/2010

## European Medicines Agency decision

P/139/2010

of 30 July 2010

on the granting of a product specific waiver for dexamethasone (EMA-000198-PIP04-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Only the English text is authentic.**



# European Medicines Agency decision

P/139/2010

of 30 July 2010

on the granting of a product specific waiver for dexamethasone (EMA-000198-PIP04-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Allergan Pharmaceuticals Ireland on 8 March 2010 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 June 2010 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

A waiver for dexamethasone, intravitreal implant in applicator, intravitreal use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 2**

This decision is addressed to Allergan Pharmaceuticals Ireland, Castlebar Road, Westport, Co. Mayo, Ireland.

Done at London, 30 July 2010

For the European Medicines Agency  
Thomas Lönngren  
Executive Director

(Signature on file)

EMA/PDCO/324454/2010

## Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-000198-PIP04-10

### Scope of the application

**Active substance(s):**

Dexamethasone

**Condition(s):**

Diabetic Macular Oedema

**Pharmaceutical form(s):**

Intravitreal implant in applicator

**Route(s) of administration:**

Intravitreal use

**Name/corporate name of the PIP applicant:**

Allergan Pharmaceuticals Ireland

### Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Allergan Pharmaceuticals Ireland submitted to the European Medicines Agency on 8 March 2010 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 15 April 2010.

## Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
  - to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Articles 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population, and with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its appendix.

London, 11 June 2010

On behalf of the Paediatric Committee  
Dr Daniel Brasseur, Chairman

(Signature on file)

## **Annex I**

### **Grounds for the granting of the waiver**

# 1. GROUNDS FOR THE GRANTING OF THE WAIVER

## 1.1. Condition

Diabetic macular oedema

### (a) Indication

Treatment of diabetic macular oedema

The waiver applies to:

- The paediatric population from birth to less than 12 years of age
- For ophthalmic insert, intravitreal use
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

The waiver applies to:

- The paediatric population from 12 years of age to less than 18 years of age
- For ophthalmic insert, intravitreal use
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.